Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives
References (33)
- et al.
Clofibrate and the liver
Lancet
(1978) - et al.
Relationship between morphological changes and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man
Atherosclerosis
(1983) - et al.
Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients
Atherosclerosis
(1983) - et al.
Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment
Atherosclerosis
(1982) - et al.
Biliary and plasma lipids and lipid-lowering chemotherapy
- et al.
Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia
Atherosclerosis
(1985) Le fenofibrate: presentation chimique, Differences avec le clofibrate
- et al.
Fenofibrate, chemical structure and how it differs from clofibrate
- et al.
The hypolipidemic effect of gemfibrozil (CI-719) in laboratory animals
- et al.
Toxicological, teratological, fertility, mutagenicity and carcinogenicity investigations with bezafibrate in animals
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug
Cancer Res
Fenofibrate: etudes de toxicologie animale en rapport avec les effets secondaires chez les malades
Nouv Press Med
Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator
J Natl Cancer Inst
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643), in rat and mouse liver
Cancer Res
Hypolipidaemic hepatic peroxisome proliferators from a novel class of chemical carcinogens
Nature
Hepatic peroxisome proliferation and carcinogenicity of hypolipidemic agents (abstr)
Cited by (113)
Thyroid hormone receptor 1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice
2018, Journal of Lipid ResearchCitation Excerpt :However, the expression of PPARα is rather low in human liver compared with mouse (22), as such fibrate stimulation exerts only moderate effects and recent studies could neither demonstrate a stimulation of ABCB4 mRNA expression by fibrates in PBC and fatty liver patients (50) nor in gallstone patients (21). However, fibrates can increase the lithogenicity of bile because of cholesterol accumulation (51) due to repression of CYP7A1 (21). It would therefore be of interest to study whether combined PPARα and THRβ stimulation would result in higher PC secretion in the bile due to synergistic effects on MDR3 expression and how this cotreatment would impact CYP7A1 levels.
Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress
2013, Journal of Surgical ResearchCitation Excerpt :Fenofibrate treatment did not improve hepatic dysfunction during the early phases after burn. Confirming these results, there are several reports that show that fibrate drugs increase ALT levels clinically, in vivo, and in vitro [26–28]. The changes were mild in all cases and it was speculated that the alteration was due to increased synthesis or decreased clearance.
Acute cholestatic hepatitis probably due to fenofibrate
2010, TherapieSafety considerations for the management of cholestatic itch
2021, Expert Opinion on Drug SafetyFenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: A preliminary analysis of its safety profile
2020, Journal of Spinal Cord Medicine